Combivent Respimat

Indicated For

Chronic obstructive pulmonary disease (COPD)

About This Medication

# Boehringer Ingelheim Cares Patient Assistance Program: How to Get Combivent Respimat at Low or No Cost ## About This Program The **Boehringer Ingelheim Cares Patient Assistance Program** provides Combivent Respimat (ipratropium bromide and albuterol sulfate) **free of charge** to eligible US patients who cannot afford their medication.[1] This program is designed to ensure that financial barriers do not prevent you from accessing the respiratory treatment you need. ## What Is Combivent Respimat? Combivent Respimat is a combination inhaler that delivers two medications to help manage chronic obstructive pulmonary disease (COPD). The medication works by relaxing airway muscles and opening breathing passages, making it easier to breathe. This program ensures that cost is not a barrier to obtaining this essential medication. ## Who Qualifies for This Program? You may be eligible for the Boehringer Ingelheim Cares Patient Assistance Program if you meet the following criteria:[1][7] - You are a **US citizen or legal resident** - You are **uninsured or underinsured** (meaning your insurance does not adequately cover Combivent Respimat or you have no insurance) - You meet the program's **income eligibility requirements** based on the Federal Poverty Level (FPL), which is adjusted annually - You have a **valid prescription** from your healthcare provider for Combivent Respimat - You are not eligible for other assistance programs such as Medicaid or Medicare's Low Income Subsidies (EXTRA HELP) ### Income Eligibility While specific income thresholds are not detailed in publicly available materials, the program uses **Federal Poverty Level (FPL) guidelines** that are updated each year.[8] Income limits vary based on household size. To determine your exact eligibility, you will need to provide financial documentation during the application process. The program is designed to help seniors and families with limited incomes. ### Insurance Requirements You are eligible if you are: - **Uninsured** (have no health insurance coverage) - **Underinsured** (have insurance that does not cover Combivent Respimat or requires unaffordable out-of-pocket costs) You are **not eligible** if you: - Have active insurance coverage that includes prescription drug benefits for this medication - Are eligible for Medicaid - Are eligible for Medicare's Low Income Subsidies (EXTRA HELP) - Have Medicare coverage that adequately covers your medication ## How to Apply ### Step 1: Gather Required Documents Before starting your application, collect the following:[3][8] - **Proof of income** (recent tax return, pay stubs, or benefit statements) - **Prescription** from your healthcare provider for Combivent Respimat - **Proof of citizenship or legal residency** (driver's license, passport, or green card) - **Insurance information** (if applicable) or proof of being uninsured - **Healthcare provider contact information** for verification ### Step 2: Complete the Application You have multiple ways to apply:[3] 1. **Online or by mail**: Download and complete the Boehringer Cares Patient Assistance Program application form at the official website 2. **By phone**: Call **(800) 556-8317** to request an application or apply with assistance 3. **With your healthcare provider**: Ask your doctor's office to help submit the application Follow all directions on the application form carefully to avoid delays. ### Step 3: Submit Your Application Submit your completed application along with all required documents. You can submit by: - Mail (address provided on the application form) - Online portal (if available) - Phone assistance Ensure your healthcare provider signs and dates the application where required. ### Step 4: Wait for Approval The program will review your application and contact you with a decision. Processing times are not specified, but you should expect to hear back within 1-2 weeks in most cases. Keep your application reference number for follow-up inquiries. ## Timeline and Medication Delivery Once approved, your Combivent Respimat will be **shipped directly to you** or to your healthcare provider's office.[1] Delivery typically occurs within 7-10 business days after approval. You will receive tracking information so you know when to expect your medication. ## What If Your Application Is Denied? If your application is denied, you have several options: 1. **Ask why**: Contact the program to understand the specific reason for denial 2. **Reapply**: If circumstances have changed, you may reapply with updated financial documentation 3. **Explore alternatives**: Ask your healthcare provider about: - Generic alternatives or other COPD medications - The Combivent Respimat Savings Card, which may offer copay assistance as low as $35 for a 30-day supply if you have insurance[2] - Other patient assistance programs - State pharmaceutical assistance programs - Nonprofit organizations that help with medication costs ## Important Disclaimers - This guide provides general information based on publicly available program details. Specific eligibility requirements, income limits, and program policies may change. - Income thresholds and eligibility criteria are adjusted annually and should be confirmed directly with the program. - This program is for US residents only. - You must provide accurate financial information. Misrepresentation may result in program termination and legal consequences. - This assistance program does not replace professional medical advice. Always consult your healthcare provider about your treatment options. ## Contact Information **Boehringer Ingelheim Cares Patient Assistance Program** - **Phone**: (800) 556-8317 - **Hours**: Monday-Friday, 7:30 AM - 5:30 PM CST - **Application**: https://www.boehringer-ingelheim.com/sites/default/files/us/2023-01/bi_cares_pap_application.pdf Do not delay seeking medical care while waiting for your application to be processed. If you need immediate medication, speak with your healthcare provider about temporary options.

Program information last verified: March 30, 2026